4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation

Although the milestone discovery of immune checkpoint blockade (ICB) has been translated into clinical practice, only a fraction of patients can benefit from it with durable responses and subsequent long-term survival. Here, we tested the anti-tumor effect of combining PD-L1 blockade with 4-1BB cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Qiu-xia, Zhu, Xin-yun, Du, Wen-wen, Wang, Hong-bin, Shen, Yu, Zhu, Yi-bei, Chen, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193033/
https://www.ncbi.nlm.nih.gov/pubmed/32391001
http://dx.doi.org/10.3389/fimmu.2020.00577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193033/
https://www.ncbi.nlm.nih.gov/pubmed/32391001
http://dx.doi.org/10.3389/fimmu.2020.00577

Ejemplares similares